Article
De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.
Leukemia research - 1 Jun 2022
Epstein-Peterson Zachary D, Spitzer Barbara, Derkach Andriy, Arango Juan E, McCarter Joseph G W, Medina-Martínez Juan S, McGovern Erin, Farnoud Noushin Rahnamay, Levine Ross L, Tallman Martin S
Abstract excerpt
Data concerning the treatment approach and clinical outcomes in younger patients with myelodysplastic syndromes (MDS) are lacking. Furthermore, published results from genomic profiling in the young adult MDS population are few. We identified patients aged 20-50 at diagnosis evaluated for de novo MDS at our institution over a 32-year period. Clinical information and results from sequencing panels were extracted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.